On April 8, 2026, Ascendis Pharma A/S reported significant improvements in treatment outcomes for children with achondroplasia in their ongoing Phase 2 COACH Trial, showing notable increases in arm span and spinal canal dimensions without compromising safety. These results included a mean arm span increase of +9.4 cm in treatment-naïve children and +7.9 cm in previously treated children, far surpassing the complications associated with previous surgical methods.